Clinical Trial Update: A Study to Explore the Safety And Tolerability of Doses of E2007 Up to a Maximum of 8 mg In Patients With Parkinson's Disease Who Experience End-of-Dose Wearing Off Motor Fluctuations [Phase 2]

View source ↗

Summary

Phase 2 study evaluating safety and tolerability of E2007 up to 8 mg in Parkinson's disease patients with end-of-dose wearing-off; trial completed with results …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• E2007

Snippet

Sponsor: Eisai Inc. | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED | Results posted: 2015-06-02